May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Acute Conjunctivitis as the Initial Symptom of Stevens-Johnson Syndrome With Ocular Complications and the Consequence of Topical Steroids
Author Affiliations & Notes
  • C. Sotozono
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • M. Ueta
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • N. Koizumi
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Research Center for Regenerative Medicine, Doshisha University, Kyoto, Japan
  • S. Hibino
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • T. Inatomi
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • S. Kinoshita
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Footnotes
    Commercial Relationships C. Sotozono, None; M. Ueta, None; N. Koizumi, None; S. Hibino, None; T. Inatomi, None; S. Kinoshita, None.
  • Footnotes
    Support Grants-in-Aid for scientific research from the Japanese Ministry of Education, Culture, Sports, Science and Technology, and Grants from the Japanese Ministry of Health, Labour and Welfare
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 361. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Sotozono, M. Ueta, N. Koizumi, S. Hibino, T. Inatomi, S. Kinoshita; Acute Conjunctivitis as the Initial Symptom of Stevens-Johnson Syndrome With Ocular Complications and the Consequence of Topical Steroids. Invest. Ophthalmol. Vis. Sci. 2007;48(13):361.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To clarify the characteristics of Stevens-Johnson syndrome (SJS) with ocular complications, we analyzed the details of a clinical course of SJS at the acute stage and evaluated whether the use of topical steroids during the first week from the onset affects the visual prognosis.

Methods:: We investigated the details of clinical manifestations at the disease onset by means of conducting structured interviews with 55 patients of SJS with chronic ocular complications from Nov 2005 to Sep 2006. The questionnaires were structured as follows; the existences and the order of high fever, conjunctivitis, skin eruptions and common cold-like symptoms, the diagnosis at disease onset, and causative drugs. We also inquired about the use of topical steroids during the first week from the onset and analyzed their effect on the visual outcomes.

Results:: Among 55 patients, 48 patients (87%) had a history of drug administration; cold remedies (18), antibiotics (11), NSAIDs (8), and others. Common cold-like symptoms (malaise, fever, sore throat, etc.) preceded skin eruptions in 44 patients. Very high fever was reported by 53 patients, and skin eruptions and acute conjunctivitis occurred in all patients. Thirty-nine patients remembered the order of their symptoms in detail, and 28 patients (72%) reported episodes of acute conjunctivitis 0.5-3 days prior to the skin eruptions. Nine patients were diagnosed with acute conjunctivitis by ophthalmologists, thereafter systemic eruptions developed. In 10 patients, eruptions and conjunctivitis occurred simultaneously. While 17 patients started topical steroid use during the first week from the onset, 21 patients received no treatment for the eye. Visual prognosis was significantly better in the group receiving topical steroids at the acute stage (P<0.00001).

Conclusions:: SJS with ocular complications is accompanied by acute conjunctivitis as an initial symptom. Administration of topical steroids during the first week following disease onset greatly improves the visual prognosis.

Keywords: cornea: clinical science • cornea: epithelium • corticosteroids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×